Grant of options

About this update from Oxford Biomedica Plc

  Grant of options   Oxford, UK - 16 May 2025: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, announces that on 16 May 2025, nil-cost share options over ordinary shares of 50 pence each in the Company were granted under the OXB 2024 Long Term Incentive Plan ("LTIP") and OXB 2024 Deferred Bonus Plan ("DBP").   2025 Grants         Type   Name of individual Title Number of share options granted under the plans prior to 2025 award Number of share options granted under 2025 award Total share options subsequently held under plans Percentage of current issued share capital under plans LTIP Frank Mathias Chief Executive Officer 580,291 350,204 930,495 0.88%   DBP Frank Mathias Chief Executive Officer 930,495 70,803 1,001,298 0.94%   LTIP Lucinda Crabtree Chief Financial Officer 170,113 201,095 371,208 0.35%   DBP Lucinda Crabtree Chief Financial Officer 371,208 15,733 386,941 0.36%   LTIP Natalie Walter Group General Counsel 201,987 73,360 275,347 0.26%   DBP Natalie Walter Group General Counsel 275,347 11,448 286,795 0.27%   LTIP RSU Natalie Walter Group General Counsel 286,795 14,204 300,999 0.28%   LTIP Sebestien Ribault Chief Business Officer 125,309 80,029 205,338 0.19%   DBP Sebestien Ribault Chief Business Officer 205,338 14,879 220,217 0.21%   LTIP RSU Sebestien Ribault Chief Business Officer 220,217 15,495 235,712 0.22%   LTIP Lisa Doman Chief People Officer 140,453 62,585 203,038 0.19%   DBP Lisa Doman Chief People Officer 203,038 10,693 213,731 0.20%   LTIP RSU Lisa Doman Chief People Officer 213,731 12,118 225,849 0.21%   LTIP Thierry Cournez Chief Operating Officer 118,007 74,132 192,139 0.18%   DBP Thierry Cournez Chief Operating Officer 192,139 12,336 204,475 0.19%   LTIP RSU Thierry Cournez Chief Operating Officer 204,475 14,353 218,828 0.21%   LTIP Kyriacos Mitrophanous Chief Innovation Officer 232,084 70,699 302,783 0.29%   DBP Kyriacos Mitrophanous Chief Innovation Officer 302,783 12,852 315,635 0.30%   LTIP RSU Kyriacos Mitrophanous Chief Innovation Officer 315,635 13,689 329,324 0.31%   LTIP Mark Caswell Site Head of UK Operations 127,896 79,168 207,064 0.20%     LTIP RSU Mark Caswell Site Head of UK Operations 207,064 15,329 222,393 0.21%   LTIP RSU Sabine Sydow Chief of Staff 20,115 9,780 29,895 0.03%   LTIP RSU Stephanie Colloud Site Head of France Operations - 12,634 12,634 0.01%     The Remuneration Committee has determined that EBITDA margin and revenue growth are the key metrics aligned with OXB's growth strategy, relevant to LTIP grant only. Details of the targets for the EBITDA margin and revenue growth measures are included in the 2024 Directors' Remuneration Report. The Notification of Dealing Forms set out below, which all represent initial notifications in respect of the grants mentioned above,  are provided in accordance with the requirements of the EU Market Abuse Regulation.   1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Frank Mathias 2. Reason for the notification a) Position/status Chief Executive Officer   b) Initial notification/ amendment Initial Notification 3. Details of the Issuer a) Name Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument   Identification code Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. c) Price(s) and volumes(s) 2025 LTIP Award   Price Volume Nil 350,204 d) Aggregated information -    Aggregate volume   -    Price     Awards granted over 350,204 shares in total     N/A   e) Date of the transaction 2025-05-16 f) Place of the transaction Outside of trading venue     1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Frank Mathias 2. Reason for the notification a) Position/status Chief Executive Officer   b) Initial notification/ amendment Initial Notification 3. Details of the Issuer a) Name Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument   Identification code Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of awards. c) Price(s) and volumes(s) 2025 DBP Award   Price Volume Nil 70,803 d) Aggregated information -    Aggregate volume   -    Price     Awards granted over 70,803 shares in total     N/A   e) Date of the transaction 2025-05-16 f) Place of the transaction Outside of trading venue     1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Lucinda Crabtree 2. Reason for the notification a) Position/status Chief Financial Officer   b) Initial notification/ amendment Initial Notification 3. Details of the Issuer a) Name Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument   Identification code Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. c) Price(s) and volumes(s) 2025 LTIP Award   Price Volume Nil 201,095 d) Aggregated information -    Aggregate volume   -    Price     Awards granted over 201,095 shares in total     N/A   e) Date of the transaction 2025-05-16 f) Place of the transaction Outside of trading venue   1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Lucinda Crabtree 2. Reason for the notification a) Position/status Chief Financial Officer   b) Initial notification/ amendment Initial Notification 3. Details of the Issuer a) Name Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument   Identification code Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of awards. c) Price(s) and volumes(s) 2025 DBP Award   Price Volume Nil 15,733 d) Aggregated information -    Aggregate volume   -    Price     Awards granted over 15,733 shares in total     N/A   e) Date of the transaction 2025-05-16 f) Place of the transaction Outside of trading venue   1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Natalie Walter 2. Reason for the notification a) Position/status General Counsel b) Initial notification/ amendment Initial Notification 3. Details of the Issuer a) Name Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument   Identification code Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. c) Price(s) and volumes(s) 2025 LTIP Award   Price Volume Nil 73,360 d) Aggregated information -    Aggregate volume   -    Price     Awards granted over 73,360 shares in total     N/A   e) Date of the transaction 2025-05-16 f) Place of the transaction Outside of trading venue   1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Natalie Walter 2. Reason for the notification a) Position/status General Counsel b) Initial notification/ amendment Initial Notification 3. Details of the Issuer a) Name Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument   Identification code Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of awards. c) Price(s) and volumes(s) 2025 DBP Award   Price Volume Nil 11,448 d) Aggregated information -    Aggregate volume   -    Price     Awards granted over 11,448 shares in total     N/A   e) Date of the transaction 2025-05-16 f) Place of the transaction Outside of trading venue   1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Natalie Walter 2. Reason for the notification a) Position/status General Counsel b) Initial notification/ amendment Initial Notification 3. Details of the Issuer a) Name Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument   Identification code Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. c) Price(s) and volumes(s) 2025 LTIP RSU Award   Price Volume Nil 14,204 d) Aggregated information -    Aggregate volume   -    Price     Awards granted over 14,204 shares in total     N/A   e) Date of the transaction 2025-05-16 f) Place of the transaction Outside of trading venue   1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Sebastien Ribault 2. Reason for the notification a) Position/status Chief Business Officer b) Initial notification/ amendment Initial Notification 3. Details of the Issuer a) Name Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument   Identification code Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. c) Price(s) and volumes(s) 2025 LTIP Award   Price Volume Nil 80,029 d) Aggregated information -    Aggregate volume   -    Price     Awards granted over 80.029 shares in total     N/A   e) Date of the transaction 2025-05-16 f) Place of the transaction Outside of trading venue   1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Sebastien Ribault 2. Reason for the notification a) Position/status Chief Business Officer b) Initial notification/ amendment Initial Notification 3. Details of the Issuer a) Name Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument   Identification code Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of awards. c) Price(s) and volumes(s) 2025 DBP Award   Price Volume Nil 14,879 d) Aggregated information -    Aggregate volume   -    Price     Awards granted over 14,879 shares in total     N/A   e) Date of the transaction 2025-05-16 f) Place of the transaction Outside of trading venue   1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Sebastien Ribault 2. Reason for the notification a) Position/status Chief Business Officer b) Initial notification/ amendment Initial Notification 3. Details of the Issuer a) Name Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument   Identification code Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. c) Price(s) and volumes(s) 2025 LTIP RSU Award   Price Volume Nil 15,495 d) Aggregated information -    Aggregate volume   -    Price     Awards granted over 15,495 shares in total     N/A   e) Date of the transaction 2025-05-16 f) Place of the transaction Outside of trading venue   1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Lisa Doman 2. Reason for the notification a) Position/status Chief People Officer b) Initial notification/ amendment Initial Notification 3. Details of the Issuer a) Name Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument   Identification code Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. c) Price(s) and volumes(s) 2025 LTIP Award   Price Volume Nil 62,585 d) Aggregated information -    Aggregate volume   -    Price     Awards granted over 62,585 shares in total     N/A   e) Date of the transaction 2025-05-16 f) Place of the transaction Outside of trading venue   1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Lisa Doman 2. Reason for the notification a) Position/status Chief People Officer b) Initial notification/ amendment Initial Notification 3. Details of the Issuer a) Name Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument   Identification code Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of awards. c) Price(s) and volumes(s) 2025 DBP Award   Price Volume Nil 10,693 d) Aggregated information -    Aggregate volume   -    Price     Awards granted over 10.693 shares in total     N/A   e) Date of the transaction 2025-05-16 f) Place of the transaction Outside of trading venue   1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Lisa Doman 2. Reason for the notification a) Position/status Chief People Officer b) Initial notification/ amendment Initial Notification 3. Details of the Issuer a) Name Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument   Identification code Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. c) Price(s) and volumes(s) 2025 LTIP RSU Award   Price Volume Nil 12,118 d) Aggregated information -    Aggregate volume   -    Price     Awards granted over 12,118 shares in total     N/A   e) Date of the transaction 2025-05-16 f) Place of the transaction Outside of trading venue   1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Thierry Cournez 2. Reason for the notification a) Position/status Chief Operating Officer b) Initial notification/ amendment Initial Notification 3. Details of the Issuer a) Name Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument   Identification code Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. c) Price(s) and volumes(s) 2025 LTIP Award   Price Volume Nil 74,132 d) Aggregated information -    Aggregate volume   -    Price     Awards granted over 74,132 shares in total     N/A   e) Date of the transaction 2025-05-16 f) Place of the transaction Outside of trading venue   1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Thierry Cournez 2. Reason for the notification a) Position/status Chief Operating Officer b) Initial notification/ amendment Initial Notification 3. Details of the Issuer a) Name Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument   Identification code Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of awards. c) Price(s) and volumes(s) 2025 DBP Award   Price Volume Nil 12,336 d) Aggregated information -    Aggregate volume   -    Price     Awards granted over 12,336 shares in total     N/A   e) Date of the transaction 2025-05-16 f) Place of the transaction Outside of trading venue   1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Thierry Cournez 2. Reason for the notification a) Position/status Chief Operating Officer b) Initial notification/ amendment Initial Notification 3. Details of the Issuer a) Name Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument   Identification code Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. c) Price(s) and volumes(s) 2025 LTIP RSU Award   Price Volume Nil 14,353 d) Aggregated information -    Aggregate volume   -    Price     Awards granted over 14,353 shares in total     N/A   e) Date of the transaction 2025-05-16 f) Place of the transaction Outside of trading venue   1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Kyriacos Mitrophanous 2. Reason for the notification a) Position/status Chief Innovation Officer b) Initial notification/ amendment Initial Notification 3. Details of the Issuer a) Name Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument   Identification code Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. c) Price(s) and volumes(s) 2025 LTIP Award   Price Volume Nil 70,699     d) Aggregated information -    Aggregate volume   -    Price     Awards granted over 70,699 shares in total     N/A   e) Date of the transaction 2025-05-16 f) Place of the transaction Outside of trading venue     1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Kyriacos Mitrophanous 2. Reason for the notification a) Position/status Chief Innovation Officer b) Initial notification/ amendment Initial Notification 3. Details of the Issuer a) Name Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument   Identification code Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of awards. c) Price(s) and volumes(s) 2025 DBP Award   Price Volume Nil 12,852     d) Aggregated information -    Aggregate volume   -    Price     Awards granted over 12,852 shares in total     N/A   e) Date of the transaction 2025-05-16 f) Place of the transaction Outside of trading venue   1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Kyriacos Mitrophanous 2. Reason for the notification a) Position/status Chief Innovation Officer b) Initial notification/ amendment Initial Notification 3. Details of the Issuer a) Name Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument   Identification code Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. c) Price(s) and volumes(s) 2025 LTIP RSU Award   Price Volume Nil 13,689     d) Aggregated information -    Aggregate volume   -    Price     Awards granted over 13,689 shares in total     N/A   e) Date of the transaction 2025-05-16 f) Place of the transaction Outside of trading venue   1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Mark Caswell   2. Reason for the notification a) Position/status Site Head of UK Operations b) Initial notification/ amendment Initial notification 3. Details of the Issuer a) Name Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument   Identification code Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. c) Price(s) and volumes(s) 2025 LTIP Award   Price Volume Nil 79,168 d) Aggregated information -    Aggregate volume   -    Price     79,168     N/A   e) Date of the transaction 2025-05-16 f) Place of the transaction Outside of trading venue   1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Mark Caswell   2. Reason for the notification a) Position/status Site Head of UK Operations b) Initial notification/ amendment Initial notification 3. Details of the Issuer a) Name Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument   Identification code Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. c) Price(s) and volumes(s) 2025 LTIP RSU Award   Price Volume Nil 15,329 d) Aggregated information -    Aggregate volume   -    Price     15,329     N/A   e) Date of the transaction 2025-05-16 f) Place of the transaction Outside of trading venue   1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Sabine Sydow   2. Reason for the notification a) Position/status Chief of Staff b) Initial notification/ amendment Initial Notification 3. Details of the Issuer a) Name Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument   Identification code Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. c) Price(s) and volumes(s) 2025 LTIP RSU Award   Price Volume Nil 9,780 d) Aggregated information -    Aggregate volume   -    Price     Awards granted over 9,780 shares in total     N/A   e) Date of the transaction 2025-05-16 f) Place of the transaction Outside of trading venue   1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Stephanie Colloud   2. Reason for the notification a) Position/status Site Head of France Operations b) Initial notification/ amendment Initial Notification 3. Details of the Issuer a) Name Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument   Identification code Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. c) Price(s) and volumes(s) 2025 LTIP RSU Award   Price Volume Nil 12,634 d) Aggregated information -    Aggregate volume   -    Price     Awards granted over 12,634 shares in total     N/A   e) Date of the transaction 2025-05-16 f) Place of the transaction Outside of trading venue   -Ends-   Enquiries:          OXB: Natalie Walter, Company Secretary - T : +44 (0) 1865 783 000 / E: [email protected] ICR Healthcare: T: +44 (0)20 3709 5700 / E:  [email protected] Mary-Jane Elliott / Angela Gray / Davide Salvi     About OXB   OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.   One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.   OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com , and follow us on LinkedIn and YouTube.

View stock analysis, news, and events for Oxford Biomedica Plc